ERBB2 and breast cancer: Due to higher TIL and TAM levels, increased PD-L1 expression, greater mutational burden, and genomic instability, TNBC and HER2+ breast cancers are considered more immunogenic compared to luminal BC, with the immune responses of these patients affecting the disease outcome [29,37,48,51,52].